Navigation Links
Monsanto Sees Growing Opportunity for Biotech Traits Globally
Date:9/11/2008

R&D Pipeline Products Poised to Deliver Yield Benefits and Value to Farmers

LONDON, Sept. 11 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) sees a significant growth opportunity in continuing to create more yield for farmers worldwide through its investment in plant biotechnology and breeding, leading to more than doubling the company's 2007's gross profit in 2012, Steve Padgette, Monsanto's vice president of biotechnology, will tell investors. Padgette will deliver his remarks as part of the UBS Best of Americas Conference on Friday in London. The opportunity for Monsanto is global and exists not just with the technologies in hand, but with what is yet to come in its R&D pipeline, Padgette will state.

"After more than 10 years of farmers planting biotech traits, the prospects for growth are substantial," Padgette said. "The opportunity for existing biotech traits outside the United States is nearly 275 million acres and a little more than a third of those acres carry Monsanto's trait technology currently."

The opportunity for international growth is most imminent and substantial in Brazil and Argentina where Monsanto is launching new trait packages. In Argentina, Monsanto has received approval for a double-stack trait combination, YieldGard(R) Corn Borer with Roundup Ready(R) Corn 2, and plans to offer the combination on more than 1 million acres in its first year of introduction. In Brazil, Monsanto received planting approval for the YieldGard Corn Borer trait and is planning for a 1 million to 2 million acre launch for the upcoming 2008-2009 season.

Padgette will also discuss the progress and momentum behind a number of projects in Monsanto's R&D pipeline, highlighting key soybean and corn projects.

"Yield is a priority for farmers," Padgette said. "When we ask farmers today what they want from us in terms of new soybean products, they universally say that they want us to bring the yield improvements they've seen in corn to soybeans."

Padgette will announce that Monsanto's high-yielding soybeans, the first biotech product in soybeans focused solely on improving yield, delivered a 6 to 10 percent yield advantage in the company's recent Latin American trials. The higher-yielding trait, which is part of the yield and stress collaboration with BASF, will be stacked on top of Monsanto's Roundup Ready 2 Yield(TM) soybean platform. Roundup Ready 2 Yield soybeans, which deliver a 7 to 11 percent yield advantage over the popular first generation Roundup Ready(R) technology, recently received regulatory approval in China for importation, placing them one step closer to the expected controlled commercial release on 1 to 2 million acres in 2009.

BASF Collaboration

Next week, Padgette will be speaking at a joint BASF and Monsanto investor event held in Ghent, Belgium. Monsanto's collaboration with BASF works to identify and commercialize novel yield and stress trait technologies for farmers.

"We are extremely pleased with the progress in our yield and stress collaboration with BASF," he said. "Since the start of the collaboration, we have been able to increase the size of our yield and stress transformation pipeline by one-third and have almost 175 field trial locations. Over 90 percent of the genes nominated by BASF have been unique, providing a nice complement to Monsanto's lead genes."

Webcast Information

Padgette's presentation slides and simultaneous audio webcast of the UBS presentation may be accessed by visiting the company's web site at http://www.monsanto.com/investors. Following tomorrow's live broadcast set for 6:30 a.m. CT, a replay of the webcast will be available for two weeks through this same link.

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: http://www.monsanto.com/.

Monsanto Company Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are "forward-looking statements," such as statements concerning Monsanto's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's most recent report on Forms 10-Q and 10-K. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.


'/>"/>
SOURCE Monsanto Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Insect Protection Technology From Monsanto Company Deregulated by USDA
2. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
3. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
4. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
5. Monsanto Executives to Address Investor Conferences in February
6. National Academy of Sciences Recognizes Monsantos Chief Technology Officer for Development of Agricultural Biotechnology
7. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
8. Monsanto and Devgen Describe New Approach to Insect-Protection
9. Monsanto Company Executives Adopt 10b5-1 Trading Plans
10. Science Magazine Recognizes Monsanto as Top Employer
11. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Research and Markets has announced the addition ... Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... is projected to reach $15,737 million by 2022 from $6,521 in ... Omic technologies segment accounted for more than half ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
Breaking Biology Technology:
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CESĀ® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
Breaking Biology News(10 mins):